These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15269827)

  • 1. Pharmacokinetics of clopidogrel after administration of a high loading dose.
    Taubert D; Kastrati A; Harlfinger S; Gorchakova O; Lazar A; von Beckerath N; Schömig A; Schömig E
    Thromb Haemost; 2004 Aug; 92(2):311-6. PubMed ID: 15269827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
    Bouman HJ; Parlak E; van Werkum JW; Breet NJ; ten Cate H; Hackeng CM; ten Berg JM; Taubert D
    J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
    Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
    von Beckerath N; Taubert D; Pogatsa-Murray G; Schömig E; Kastrati A; Schömig A
    Circulation; 2005 Nov; 112(19):2946-50. PubMed ID: 16260639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Herbert JM; Savi P
    Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR).
    Součková L; Opatřilová R; Suk P; Čundrle I; Pavlík M; Zvoníček V; Hlinomaz O; Šrámek V
    Eur J Clin Pharmacol; 2013 Mar; 69(3):309-17. PubMed ID: 22890586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
    von Beckerath N; von Beckerath O; Koch W; Eichinger M; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2005 Apr; 16(3):199-204. PubMed ID: 15795539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans.
    Cushing DJ; Souney PF; Cooper WD; Mosher GL; Adams MP; Machatha S; Zhang B; Kowey PR
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):3-8. PubMed ID: 21933229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.
    Bal Dit Sollier C; Berge N; Boval B; Hovsepian L; Drouet L
    Thromb Haemost; 2009 Jan; 101(1):116-22. PubMed ID: 19132197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study.
    Collet JP; Funck-Brentano C; Prats J; Salem JE; Hulot JS; Guilloux E; Hu MY; He K; Silvain J; Gallois V; Brugier D; Anzaha G; Galier S; Nicolas N; Montalescot G
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):43-53. PubMed ID: 26386578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
    Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma.
    Liu C; Lu Y; Sun H; Yang J; Liu Y; Lai X; Gong Y; Liu X; Li Y; Zhang Y; Chen X; Zhong D
    J Pharm Biomed Anal; 2018 Feb; 149():394-402. PubMed ID: 29154109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
    Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.